Evaluation of the Efficacy of Restylane Silk in the Correction of Tear Trough Deformity

NCT ID: NCT02689947

Last Updated: 2018-03-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective single center study to evaluate the safety and effectiveness of Restylane Silk for treatment of tear trough correction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tear Trough Deformity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Restylane Silk

open label no placebo control

Group Type EXPERIMENTAL

Restylane Silk

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Restylane Silk

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Is a healthy male or female between 21 and 65 years old
2. Tear trough deformity, Hirmand Type-1 and Type-2
3. Is voluntarily willing to consent to participate in the study
4. Is willing to comply with all requirements of the study including being photographed, follow post treatment care instructions, to attend all treatment, and follow up visits
5. Willingness to waive rights to use of still photos of themselves for research, marketing, or promotional reasons, including on the internet and on social media outlets.
6. Willingness to refrain from other surgical, laser, or injectable treatments in the periorbital region during the entire duration of the study.
7. Ability to provide informed consent.

Exclusion Criteria

1. Marked delineation of the inferior orbital rim in the lateral aspect of the eyelid/orbit
2. Use of botulinum toxin in the periorbital region within the past 6 months.
3. Treatment with injectable fillers in the midface or periorbital region within the past 2 years or treatment at any time in the past with a permanent filler in the midface or periorbital region such as silicone, or PMMA (Artefill)
4. Laser skin resurfacing of the periorbital region within the past one year.
5. History of lower eyelid blepharoplasty or periorbital surgery in tear trough region.
6. The subject has a coagulation disorder or is currently using anti-coagulation medication
7. History of facial nerve palsy.
8. Inability to discontinue the use of nonsteroidal anti-inflammatory drugs or anticoagulants prior to treatment.
9. Current participation in another active clinical trial protocol
10. Presence of malar festoons
11. Active cutaneous infections
12. Allergy or sensitivity to benzocaine, lidocaine, prilocaine, or tetracaine.
13. Pregnant or nursing females
14. Other factors as deemed by the Principal Investigator that would make a subject unqualified for participation.
15. The subject has a history of keloids or compromised wound healing
16. The subject has a known adverse reaction to previous injection with hyaluronic acid or other subcutaneously injected device
Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nashville Centre for Laser and Facial Surgery

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Restylane Silk for Tear Trough

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Sculptra Aesthetic Post-Approval Study
NCT02425943 COMPLETED PHASE4